Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension

URN to cite this document:: urn:nbn:de:bvb:355-epub-415463
DOI to cite this document:: 10.5283/epub.41546

Milling, Rikke Vilsbøll ; Grimm, Daniela ; Krüger, Marcus ; Grosse, Jirka

Preview

License: Creative Commons Attribution 4.0
PDF - Published Version
(1MB)

Date of publication of this fulltext: 11 Feb 2020 10:20

Alternative links to fulltext:DOI Publisher

Details

Preview

Export bibliographical data

Abstract

Medullary thyroid cancer (MTC) is a rare malignancy with a poor prognosis. First line therapy is surgery, which is the only curative method of the disease. However, in non-operable cases or with tumor progression and metastases, a systemic treatment is necessary. This form of cancer is often insensitive to conventional chemotherapy, but the use of tyrosine kinase inhibitors (TKIs), such as ...